Search

Displaying results 1181 - 1190 of 4539 in total
  1. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload. … [T28] First approved by the FDA in 1991,[L11743] isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of

  2. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.

  3. Drug

    Hydroxystilbamidine

    go.drugbank.com/drugs/DB14753
    Approved

    Hydroxystilbamidine isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than amphotericin B. Hydroxystilbamidine ...

  4. Drug

    Tetracycline

    go.drugbank.com/drugs/DB00759
    ApprovedInvestigationalVet approvedWithdrawn

    Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. … It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site.

    Products: TETRACICLINA MK CLORHIDRATO 500MG CAPSULAS, KATITRA
  5. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.

  6. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate … Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the

  7. Drug

    Dolutegravir

    go.drugbank.com/drugs/DB08930
    ApprovedInvestigational

    [A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.

  8. Drug

    Human calcitonin

    go.drugbank.com/drugs/DB06773
    Approved

    Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calci...

  9. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]

  10. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    [L39030] This indication is valid in the US, Europe, and Canada. … L10166] which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug.